Clinical Trial Update: A Study to Examine APL-130277 in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update for APL-130277 in Parkinson's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• APL-130277 (APL-130277)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-07-30